SecSonar.com

Zymeworks Inc. (ZYME)

Zymeworks Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Zymeworks Inc. (ZYME) is a Biotechnology company based in CA with a market capitalization of $1.9B. Revenue grew 38.9% year-over-year and free cash flow was negative at -$34.5M. This page tracks ZYME's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

CA · 299 employees · IPO Apr 28, 2017

Valuation

Valuation & price

$23.93 · as of May 17, 2026 · -16.2% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

6.89

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$28.53$20.47$12.41Jul 25Dec 25Jul 26Jul 7, 25$13.08Jul 9, 25$13.57Jul 11, 25$13.34Jul 15, 25$12.88Jul 17, 25$14.48Jul 21, 25$14.32Jul 23, 25$14.29Jul 25, 25$13.33Jul 29, 25$13.51Jul 31, 25$12.56Aug 4, 25$12.60Aug 6, 25$12.41Aug 11, 25$12.44Aug 13, 25$13.94Aug 15, 25$14.36Aug 19, 25$14.10Aug 21, 25$14.39Aug 25, 25$14.57Aug 27, 25$14.93Aug 29, 25$14.81Sep 3, 25$14.14Sep 5, 25$15.05Sep 9, 25$15.23Sep 11, 25$16.32Sep 16, 25$15.84Sep 18, 25$16.49Sep 22, 25$16.53Sep 24, 25$16.30Sep 26, 25$16.60Sep 30, 25$17.08Oct 2, 25$16.90Oct 6, 25$16.68Oct 8, 25$16.68Oct 10, 25$18.06Oct 14, 25$18.23Oct 16, 25$18.55Oct 21, 25$17.93Oct 23, 25$17.41Oct 27, 25$18.47Oct 29, 25$19.38Oct 31, 25$19.09Nov 4, 25$18.16Nov 6, 25$17.90Nov 10, 25$18.05Nov 12, 25$19.37Nov 14, 25$18.52Nov 18, 25$22.99Nov 20, 25$23.82Nov 25, 25$26.18Nov 28, 25$26.71Dec 2, 25$25.10Dec 4, 25$26.52Dec 8, 25$26.41Dec 10, 25$25.87Dec 12, 25$25.48Dec 16, 25$25.85Dec 18, 25$26.40Dec 22, 25$27.62Dec 24, 25$26.86Dec 29, 25$26.74Jan 2, 26$26.62Jan 6, 26$24.18Jan 8, 26$23.10Jan 12, 26$23.16Jan 14, 26$24.62Jan 16, 26$23.47Jan 21, 26$23.95Jan 23, 26$23.24Jan 27, 26$23.25Jan 29, 26$22.38Feb 2, 26$23.17Feb 4, 26$23.11Feb 9, 26$22.51Feb 11, 26$22.83Feb 13, 26$22.60Feb 18, 26$22.91Feb 20, 26$22.72Feb 24, 26$23.63Feb 26, 26$23.81Mar 2, 26$23.31Mar 4, 26$25.23Mar 6, 26$24.08Mar 10, 26$25.46Mar 12, 26$23.23Mar 17, 26$24.04Mar 19, 26$23.90Mar 23, 26$24.02Mar 25, 26$24.23Mar 27, 26$24.18Mar 31, 26$25.04Apr 2, 26$25.80Apr 7, 26$26.00Apr 9, 26$27.35Apr 13, 26$26.17Apr 15, 26$27.73Apr 17, 26$27.80Apr 22, 26$28.53Apr 24, 26$28.10Apr 28, 26$27.94Apr 30, 26$27.54May 4, 26$26.78May 6, 26$27.61May 8, 26$23.89May 12, 26$23.90May 14, 26$23.96May 18, 26$24.43May 20, 26$24.84May 22, 26$25.61May 28, 26$25.48Jun 1, 26$24.54Jun 3, 26$24.35Jun 5, 26$24.04Jun 9, 26$23.26Jun 11, 26$22.97Jun 15, 26$23.26Jun 17, 26$23.14Jun 22, 26$23.26Jun 24, 26$24.30Jun 26, 26$24.15Jul 2, 26$26.31
$12.0252-week range$28.56
Loading valuation history…

Fundamentals

Key fundamentals

$1.9B

Market cap

38.9%

Revenue growth (YoY)

100.0%

Gross margin

-$34.5M

Free cash flow (USD)

-$210.5M

Net debt

Net cash position

-0.7%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$11.0MFY 2017$51.8MFY 2018$53.0MFY 2019$29.5MFY 2020$39.0MFY 2021$26.7MFY 2022$412.5MFY 2023$76.0MFY 2024$76.3MFY 2025$106.0M
$11M$106M

Free cash flow by year

2016 → 2025

FY 2016$-40.7MFY 2017$-2.9MFY 2018$20.8MFY 2019$-95.7MFY 2020$-157.7MFY 2021$-205.7MFY 2022$131.0MFY 2023$-122.4MFY 2024$-113.1MFY 2025$-34.5M
-$40.7M-$34.5M

Gross margin by year

2021 → 2025

FY 2021100.0%FY 2022100.0%FY 2023-88.1%FY 2024100.0%FY 2025100.0%
100.0%100.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventMerger AgreementJun 29, 2026Filing
  • 8-K eventShare Repurchase ProgramMay 14, 2026Filing
  • 8-K eventEarnings ReleaseMay 7, 2026Filing
  • Quarterly report10-Q FiledMay 7, 2026Filing
  • 8-K eventCFO AppointmentApr 1, 2026Filing

Questions

Frequently asked questions

What is Zymeworks Inc.'s market cap?

Zymeworks Inc. (ZYME) has a market capitalization of $1.9B.

What is ZYME's P/E ratio?

A meaningful P/E ratio is not available for ZYME — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is ZYME's price-to-book (P/B) ratio?

ZYME trades at 6.89 times book value per share.

Are insiders buying ZYME stock?

SEC Form 4 filings show no open-market insider buys at Zymeworks Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

AAPG

Ascentage Pharma Group International

$1.9B

BCRX

BioCryst Pharmaceuticals, Inc.

$1.9B

HRMY

Harmony Biosciences Holdings, Inc.

$1.8B

GLPG

Galapagos N.V.

$1.9B

ABCL

AbCellera Biologics Inc.

$1.9B

ADMA

ADMA Biologics, Inc.

$1.9B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.